Company Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBankin. Its lead therapeutic programs include CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease.
In addition, the company is developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.
Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.
The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.
Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Robert Hariri |
Contact Details
Address: 170 Park Avenue Florham Park, New Jersey 07932 United States | |
| Phone | 908 768 2170 |
| Website | celularity.com |
Stock Details
| Ticker Symbol | CELU |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001752828 |
| CUSIP Number | 151190105 |
| ISIN Number | US1511902041 |
| Employer ID | 83-1702591 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, Chief Executive Officer and Chairman |
| David C. Beers C.F.A. | Chief Financial Officer |
| John R. Haines | Senior EVice President, Corporate Secretary, Global Manager and Chief Administrative Officer |
| Carlos Ramirez | SVice President of Investor Relations |
| Dr. Stephen A. Brigido D.P.M. | President of Degenerative Diseases |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology and Drug Safety |
| Tim Wilk | Senior Vice President of Technical Operations |
| David Jakob Lemus CPA, M.S., MBA | Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-K | Annual Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 10, 2025 | RW | Filing |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | EFFECT | Notice of Effectiveness |